Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


biotechdispatch.com.au > news > us-health-agency-funds-broad-access-trial-for-melbourne-biotechs-als-drug

US health agency funds broad access trial for Melbourne biotech's ALS drug

5+ day, 12+ hour ago   (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...


biotechdispatch.com.au > news > arovella-therapeutics-moves-off-the-shelf-cell-therapy-from-lab-to-patients

Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients

1+ week, 17+ hour ago   (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...


biotechdispatch.com.au > news > recce-advances-pivotal-diabetic-foot-infection-trial-with-active-antibiotic-comparator-arm

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

3+ week, 4+ day ago   (340+ words) Recce Pharmaceuticals has secured Australian ethics approval to expand its pivotal Phase 3 trial of RECCE 327 Topical Gel by adding a head-to-head study against antibiotics currently used to treat diabetic foot infections. The Human Research Ethics Committee has approved an amendment…...